Charm Therapeutics Raises $50M to Simulate Protein-Drug Interactions With AI
Charm Therapeutics secures $50 million in Series A funding to advance its DragonFold platform, which uses artificial intelligence to predict how drug molecules bind to target proteins. This co-folding technology aims to accelerate the discovery of highly selective precision medicines.
Charm Therapeutics secures $50 million in a Series A funding round to develop its DragonFold platform, an artificial intelligence system that simulates how drug molecules interact with target proteins. Unlike older methods like X-ray crystallography that take weeks or months, this machine learning approach produces accurate structural predictions in seconds.
The startup's technology tackles a major challenge in drug discovery by predicting protein-ligand co-folding, which is the process of determining exactly how a small drug molecule and a target protein fit together. When a protein meets a compatible binder, its entire structure can transform, making this complex interplay incredibly difficult to simulate without advanced AI.
By accurately mapping these precise 3D interactions, DragonFold allows researchers to screen billions of molecules and make precision modifications to drug candidates. This capability enables the design of drugs that bind tightly and selectively to disease-causing proteins while avoiding similar proteins necessary for normal human functioning.